Skip to content

Study · Randomized controlled trial · n = 52 · 2010

4 results

Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.

Schoedel KA, Meier D, Chakraborty B, Manniche PM, Sellers EM

Clinical pharmacology and therapeutics2 Jun 2010Cited by 34 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialActivity measurement

    In recreational stimulant users, tesofensine did not differ significantly from placebo on the reported subjective measures.

    In plain wordsIn recreational stimulant users, tesofensine did not differ significantly from placebo on the reported subjective measures.

    Outcome
    No significant changeSubjective abuse-related measures
    Study

    n = 52

    Comparator
    Placebo
    Outcome group
    Addiction, withdrawal and alcohol intake · Nervous system and cognition
    Studied dose
    Dose not stated · 48 hours after a single doseAs given in this study (human).

    Source sentences

    Summary
    The effects of tesofensine were not significantly different from those of placebo and were lower than those of D-amphetamine 30 mg on all primary and most secondary measures.
    2 context sentences
    Summary · context
    The study results show that the effects of D-amphetamine were significantly greater than those of placebo on all primary and secondary subjective measures.
    Summary · context
    It was designed as a single-dose, randomized, double-blind, crossover study involving tesofensine vs. placebo, D-amphetamine (positive control for dopaminergic/stimulant effects), bupropion, and atomoxetine (negative/unscheduled controls) in recreational stimulant users (N = 52).
  2. 02HumanRandomized controlled trialActivity measurement

    In recreational stimulant users, tesofensine effects were lower than D-amphetamine on all primary and most secondary subjective measures.

    In plain wordsIn recreational stimulant users, tesofensine effects were lower than D-amphetamine on all primary and most secondary subjective measures.

    Outcome
    DecreaseSubjective abuse-related measures
    Study

    n = 52

    Comparator
    D-amphetamine 30 mg
    Outcome group
    Addiction, withdrawal and alcohol intake · Nervous system and cognition
    Studied dose
    Dose not stated · 48 hours after a single doseAs given in this study (human).

    Source sentences

    Summary
    The effects of tesofensine were not significantly different from those of placebo and were lower than those of D-amphetamine 30 mg on all primary and most secondary measures.
    2 context sentences
    Summary · context
    The study results show that the effects of D-amphetamine were significantly greater than those of placebo on all primary and secondary subjective measures.
    Summary · context
    It was designed as a single-dose, randomized, double-blind, crossover study involving tesofensine vs. placebo, D-amphetamine (positive control for dopaminergic/stimulant effects), bupropion, and atomoxetine (negative/unscheduled controls) in recreational stimulant users (N = 52).
  3. 03HumanRandomized controlled trialActivity measurement

    In recreational stimulant users, tesofensine effects were either lower than or not different from those of bupropion or atomoxetine.

    In plain wordsIn recreational stimulant users, tesofensine effects were either lower than or not different from those of bupropion or atomoxetine.

    Outcome
    MixedAbuse-related effects
    Study

    n = 52

    Comparator
    Bupropion or atomoxetine
    Outcome group
    Addiction, withdrawal and alcohol intake · Nervous system and cognition
    Studied dose
    Dose not stated · 48 hours after a single doseAs given in this study (human).

    Source sentences

    Summary
    The effects of tesofensine were either lower than or not different from those of bupropion or atomoxetine.
    1 context sentence
    Summary · context
    It was designed as a single-dose, randomized, double-blind, crossover study involving tesofensine vs. placebo, D-amphetamine (positive control for dopaminergic/stimulant effects), bupropion, and atomoxetine (negative/unscheduled controls) in recreational stimulant users (N = 52).
  4. 04HumanRandomized controlled trialActivity measurement

    In recreational stimulant users, tesofensine effects were either lower than or not different from atomoxetine effects.

    In plain wordsIn recreational stimulant users, tesofensine effects were either lower than or not different from atomoxetine effects.

    Outcome
    MixedAbuse-related effects
    Study

    n = 52

    Comparator
    Atomoxetine
    Outcome group
    Addiction, withdrawal and alcohol intake · Nervous system and cognition
    Studied dose
    Dose not stated · 48 hours after a single doseAs given in this study (human).

    Source sentences

    Summary
    The effects of tesofensine were either lower than or not different from those of bupropion or atomoxetine.
    1 context sentence
    Summary · context
    It was designed as a single-dose, randomized, double-blind, crossover study involving tesofensine vs. placebo, D-amphetamine (positive control for dopaminergic/stimulant effects), bupropion, and atomoxetine (negative/unscheduled controls) in recreational stimulant users (N = 52).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.